What is cancer anorexia-cachexia syndrome? A historical perspective.

J R Coll Physicians Edinb

Section of Palliative Medicine and Supportive Oncology, The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA.

Published: September 2009

Cancer anorexia-cachexia syndrome (CACS) is a lethal but poorly defined involuntary wasting disorder. Loss of skeletal muscle and fat distinguishes it from starvation. Cachexia has been described as a clinical syndrome since ancient times, and the poor prognosis has long been acknowledged. In this article we have reviewed historical perspectives on cancer cachexia, and commented on modern definitions. In cancer cachexia, most historical descriptions included anorexia, wasting and a pale complexion. Other associated symptoms, such as fatigue, early satiety and taste changes, were inconsistently described. Newer descriptions have not significantly expanded the clinical picture.Today, there is still no consensus definition, hindering research on early diagnosis and effective therapy. The language descriptors used to characterise the syndrome are important. For example, the word 'cachexia' itself may mislead; perhaps cancer-related wasting syndrome is more accurate. Cancer anorexia-cachexia syndrome is a disorder associated with high morbidity and mortality, and deserves greater attention in both clinical and translational research.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cancer anorexia-cachexia
12
anorexia-cachexia syndrome
8
cancer cachexia
8
cancer
5
syndrome
5
anorexia-cachexia syndrome?
4
syndrome? historical
4
historical perspective
4
perspective cancer
4
syndrome cacs
4

Similar Publications

Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation.

Front Immunol

December 2024

Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.

Background: Cachexia is a leading cause of death among individuals with advanced cancer, yet effective pharmacological treatments are lacking. In this single-center retrospective study, we aimed to investigate the efficacy and safety of tocilizumab for the treatment of cancer cachexia accompanied by systemic hyperinflammation.

Methods: Data were collected from 20 patients treated with tocilizumab and a control group of 20 patients matched for age, sex, and comorbidities.

View Article and Find Full Text PDF

Treatment of choice for malignant gastric outlet obstruction: More than clearing the road.

World J Gastrointest Endosc

November 2024

Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China.

In this editorial, we comment on the in-press article in the concerning the treatment of malignant gastric outlet obstruction (mGOO). The original theory of treatment involves bypassing the obstruction or reenabling the patency of the passage. Conventional surgical gastroenterostomy provides long-term relief of symptoms in selected patients, with substantial morbidity and a considerable rate of delayed gastric emptying.

View Article and Find Full Text PDF

GDF15 research from bench to bedside.

Cancer Cell

November 2024

St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address:

Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions with no highly effective treatment. A phase 2 study of a therapeutic GDF15 monoclonal antibody in the New England Journal of Medicine suggests that effective treatment of anorexia/cachexia in cancer may be approaching.

View Article and Find Full Text PDF
Article Synopsis
  • Cancer cachexia frequently occurs in advanced non-small cell lung cancer (NSCLC) and its impact on chemotherapy is not fully understood.
  • A study involving 887 NSCLC patients identified that 31.7% experienced weight loss indicative of cachexia, with variations in quality of life (QOL) observed across different treatment groups.
  • Results showed that quality of life declined more significantly in chemotherapy patients compared to those receiving targeted therapies or immune checkpoint inhibitors, especially within the first week of treatment.
View Article and Find Full Text PDF
Article Synopsis
  • The hormone ghrelin plays a protective role in cancer-related anorexia-cachexia syndrome (CACS), with its levels rising to help combat weight loss and anorexia in cancer patients.
  • A study found that deleting ghrelin worsened body weight and fat loss in mice with cancer, while deleting LEAP2, a ghrelin antagonist, seemed to lessen the severity of CACS.
  • In human patients with CACS, a lower ratio of plasma LEAP2 to total ghrelin was associated with better weight stability, indicating a possible protective mechanism against worsening CACS.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!